Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors

详细信息    查看全文

• 作者：Marius M. Hoeper^a ; ^{Hoeper.Marius@mh-hannover.de} ; James R. Klinger^b ; Raymond L. Benza^c ; Gerald Simonneau^d ; David Langleben^e ; Robert Naeije^f ; Paul A. Corris^g
• 关键词：Pulmonary arterial hypertension ; sGC stimulator ; Soluble guanylate cyclase ; Riociguat
• 刊名：Respiratory Medicine
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：122
• 期：supp_S1
• 页码：S18-S22
• 全文大小：303 K
• 卷排序：122

文摘

Patients not responding to PDE-5i therapy may have inadequate synthesis of cGMP. Such patients may response to soluble guanylate cyclase stimulators. The RESPITE trial will help determine if response to therapy varies in PAH patients.